drugset / Trial / NCT00768612
Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese subjects that have a sudden worsening of their symptoms of schizophrenia. The study will also assess the efficacy of vabicaserin and compare it to risperidone.
Timeline
- Start
- 2008-11
- Primary completion
- 2009-07
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Risperidone | Other / unclassified | 4 mg | — |
| Subject | vabicaserin | Small molecule | 50 mg | — |
| Subject | vabicaserin | Small molecule | 150 mg | — |
| Subject | vabicaserin | Small molecule | 300 mg | — |